Contact
searchSearch
HMP Global

Health Care Policy and Legislation

conference coverage


Conference Coverage
State-Level Initiatives in Drug Pricing, PBM Reform, and Utilization Management
10/16/2024
Discover the latest state-level pharmacy policy trends, including pharmacy benefit manager (PBM) regulations and utilization management practices, from the eye-opening AMCP Nexus 2024 session.
Discover the latest state-level pharmacy policy trends, including pharmacy benefit manager (PBM) regulations and utilization management practices, from the eye-opening AMCP Nexus 2024 session.
Discover the latest state-level...
10/16/2024
First Report Managed Care
Conference Coverage
PBM Legislation: Navigating Congressional Delays and Encouraging Progress
04/17/2024
Explore the world of federal pharmacy benefit manager (PBM) legislation and its potential impact on stakeholders in this in-depth analysis presented by Ross Margulies, JD, MPH, Partner and Co-Chair Healthcare and Life Sciences Coverage &...
Explore the world of federal pharmacy benefit manager (PBM) legislation and its potential impact on stakeholders in this in-depth analysis presented by Ross Margulies, JD, MPH, Partner and Co-Chair Healthcare and Life Sciences Coverage &...
Explore the world of federal...
04/17/2024
First Report Managed Care
Conference Coverage
FDA Oncology Approvals Commonly Involve Surrogate Endpoints, Analysis Shows
06/02/2023
In an updated analysis presented at the 2023 ASCO Annual Meeting, researchers examined the frequency with which surrogate endpoints were used to support oncology approvals from 2006 to 2022.
In an updated analysis presented at the 2023 ASCO Annual Meeting, researchers examined the frequency with which surrogate endpoints were used to support oncology approvals from 2006 to 2022.
In an updated analysis presented...
06/02/2023
First Report Managed Care
Conference Coverage
Evolving Implications of the Inflation Reduction Act's Drug Pricing Policies
05/12/2023
Experts at Asembia's AXS23 Summit discussed upcoming changes in the Inflation Reduction Act (IRA) and how stakeholders can be strategically prepared.
Experts at Asembia's AXS23 Summit discussed upcoming changes in the Inflation Reduction Act (IRA) and how stakeholders can be strategically prepared.
Experts at Asembia's AXS23...
05/12/2023
First Report Managed Care
Conference Coverage
Navigating Specialty Legislation: Solutions for Shared Pharmacy Services
05/11/2023
Speakers at Asembia's AXS23 Summit discussed the increased demand for shared services pharmacy models, including common regulatory problems and potential solutions.
Speakers at Asembia's AXS23 Summit discussed the increased demand for shared services pharmacy models, including common regulatory problems and potential solutions.
Speakers at Asembia's AXS23...
05/11/2023
First Report Managed Care
Conference Coverage
How the Accelerated Approval Pathway Impacts Rare Diseases, Cancer, and Alzheimer Disease
03/22/2023
Speakers at AMCP 2023 offered insight into the accelerated approval pathway's design and how drugs approved through this pathway impact managed care considerations for a variety of disease states.
Speakers at AMCP 2023 offered insight into the accelerated approval pathway's design and how drugs approved through this pathway impact managed care considerations for a variety of disease states.
Speakers at AMCP 2023 offered...
03/22/2023
First Report Managed Care
Conference Coverage
Upcoming Federal Legislative, Regulatory Updates
10/14/2022
The AMCP Policy and Government Relations team discusses the latest and upcoming federal legislative and regulatory updates regarding health policy at AMCP Nexus 2022.
The AMCP Policy and Government Relations team discusses the latest and upcoming federal legislative and regulatory updates regarding health policy at AMCP Nexus 2022.
The AMCP Policy and Government...
10/14/2022
First Report Managed Care
Conference Coverage
AMCP Highlights Upcoming Legislative and Regulatory Updates
03/30/2022
In one of the first sessions of AMCP 2022, speakers offered updates on legislation and regulatory changes that could affect formularies and medication management decisions by health plans in the upcoming year.
In one of the first sessions of AMCP 2022, speakers offered updates on legislation and regulatory changes that could affect formularies and medication management decisions by health plans in the upcoming year.
In one of the first sessions of...
03/30/2022
First Report Managed Care

Behind the Bill

Behind the Bill
SCOTUS Takes on the Nondelegation Doctrine: Surprising Reactions and What They Mean for Agency Power
04/02/2025
The Supreme Court recently heard arguments in Federal Communication Commission (FCC) v Consumers’ Research, a case that I covered in February and one that could dramatically reshape federal agency authority through the nondelegation...
The Supreme Court recently heard arguments in Federal Communication Commission (FCC) v Consumers’ Research, a case that I covered in February and one that could dramatically reshape federal agency authority through the nondelegation...
The Supreme Court recently heard...
04/02/2025
First Report Managed Care
Behind the Bill
Dr Oz’s Prescription for Making Medicaid “Viable at Every Level”
03/26/2025
On Tuesday, March 25, 2025, the Senate Finance Committee voted to advance Dr Mehmet Oz in his confirmation as the next head of the Centers for Medicare and Medicaid Services (CMS).1 The full Senate vote is expected “soon” (whatever that...
On Tuesday, March 25, 2025, the Senate Finance Committee voted to advance Dr Mehmet Oz in his confirmation as the next head of the Centers for Medicare and Medicaid Services (CMS).1 The full Senate vote is expected “soon” (whatever that...
On Tuesday, March 25, 2025, the...
03/26/2025
First Report Managed Care
Behind the Bill
The $880 Billion Question Continues: Dr Oz's Confirmation and the Future of Medicaid
03/19/2025
Last week, I explored the $880 billion question facing Congress—whether lawmakers could achieve their budget goals without cutting Medicaid. This week, that question took center stage as Dr Mehmet Oz, President Trump's nominee to lead the...
Last week, I explored the $880 billion question facing Congress—whether lawmakers could achieve their budget goals without cutting Medicaid. This week, that question took center stage as Dr Mehmet Oz, President Trump's nominee to lead the...
Last week, I explored the $880...
03/19/2025
First Report Managed Care
Behind the Bill
The $880 Billion Question: Can Congress Cut Spending Without Touching Medicaid?
03/12/2025
I’d like to step away from administrative law for a moment to provide a quick update on Medicaid. With news coming from all sides, what does the future of Medicaid actually look like? The House of Representatives narrowly passed a budget...
I’d like to step away from administrative law for a moment to provide a quick update on Medicaid. With news coming from all sides, what does the future of Medicaid actually look like? The House of Representatives narrowly passed a budget...
I’d like to step away from...
03/12/2025
First Report Managed Care
Behind the Bill
RFK Jr’s Public Comment Ban: The Silent Shift in Health Care Rulemaking
03/05/2025
The erosion of administrative law continues, and with it, the dismantling of decades-long precedent. In June, the Supreme Court overturned a 40-year-old doctrine that allowed federal agencies to interpret their own ambiguous statutes. Later...
The erosion of administrative law continues, and with it, the dismantling of decades-long precedent. In June, the Supreme Court overturned a 40-year-old doctrine that allowed federal agencies to interpret their own ambiguous statutes. Later...
The erosion of administrative...
03/05/2025
First Report Managed Care
Behind the Bill
Prevention Over Pills? The First 2 Weeks of Health Care’s New Direction
02/26/2025
The dust has barely settled from Robert F Kennedy Jr’s confirmation as Secretary of Health and Human Services (HHS), but the changes are already coming fast and furious—a key theme of the Trump Administration’s actions within the last several...
The dust has barely settled from Robert F Kennedy Jr’s confirmation as Secretary of Health and Human Services (HHS), but the changes are already coming fast and furious—a key theme of the Trump Administration’s actions within the last several...
The dust has barely settled from...
02/26/2025
First Report Managed Care
Behind the Bill
The Nondelegation Doctrine: The Next Constitutional Showdown (Part 2)
02/19/2025
Last week, I explored the potential revival of the nondelegation doctrine through Federal Communication Commission v Consumers’ Research. Today, I want to examine what this could mean for health care regulation by considering the parallels...
Last week, I explored the potential revival of the nondelegation doctrine through Federal Communication Commission v Consumers’ Research. Today, I want to examine what this could mean for health care regulation by considering the parallels...
Last week, I explored the...
02/19/2025
First Report Managed Care
Behind the Bill
The Nondelegation Doctrine: The Next Constitutional Showdown (Part 1)
02/12/2025
Just when you thought the dust had settled from the Chevron decision, the Supreme Court is gearing up to hear arguments in Federal Communications Commission v Consumers' Research next month, potentially reviving the long-dormant nondelegation...
Just when you thought the dust had settled from the Chevron decision, the Supreme Court is gearing up to hear arguments in Federal Communications Commission v Consumers' Research next month, potentially reviving the long-dormant nondelegation...
Just when you thought the dust...
02/12/2025
First Report Managed Care
Behind the Bill
No, President Trump Did Not Actually Sign an Executive Order That Would Increase Drug Costs for Beneficiaries
02/05/2025
On inauguration day, President Trump issued an executive order rescinding several Biden-era health care initiatives, including 3 experimental drug pricing models developed by the Center for Medicare and Medicaid Innovation (CMMI). Oh boy did...
On inauguration day, President Trump issued an executive order rescinding several Biden-era health care initiatives, including 3 experimental drug pricing models developed by the Center for Medicare and Medicaid Innovation (CMMI). Oh boy did...
On inauguration day, President...
02/05/2025
First Report Managed Care
Behind the Bill
Robert F. Kennedy Jr’s Confirmation and the Unexpected Turn in the Drug Pricing Debate
01/29/2025
The Plot Thickens in Drug Pricing Drama Just when you thought the drug pricing debate couldn't get more interesting, Robert F. Kennedy Jr adds an unexpected twist. During closed-door Senate meetings, President Trump’s US Department of...
The Plot Thickens in Drug Pricing Drama Just when you thought the drug pricing debate couldn't get more interesting, Robert F. Kennedy Jr adds an unexpected twist. During closed-door Senate meetings, President Trump’s US Department of...
The Plot Thickens in Drug...
01/29/2025
First Report Managed Care

Subscribe and Stay Ahead With Daily Industry Insights

First Report Managed Care Newsletter

Trending Articles

News
New Respiratory Syncytial Virus Prevention Options on the Horizon for Older Adults
04/21/2023
“It is likely that multiple immunization strategies with complementary value, unique advantages, and use-case scenarios will shape the RSV prevention landscape," researchers said.
“It is likely that multiple immunization strategies with complementary value, unique advantages, and use-case scenarios will shape the RSV prevention landscape," researchers said.
“It is likely that multiple...
04/21/2023
Pharmacy Learning Network
News
Tildrakizumab No Better Than Placebo for Ankylosing Spondylitis
06/09/2023
A 48-week trial of tildrakizumab in patients with ankylosing spondylitis was terminated early after researchers found that the drug had no efficacy in comparison to placebo.
A 48-week trial of tildrakizumab in patients with ankylosing spondylitis was terminated early after researchers found that the drug had no efficacy in comparison to placebo.
A 48-week trial of tildrakizumab...
06/09/2023
First Report Managed Care
News
Dupilumab Reduces COPD Exacerbations in Patients With Type 2 Inflammation
07/07/2023
“In some patients with COPD, type 2 inflammation may increase exacerbation risk and may be indicated by elevated blood eosinophil counts,” said researchers. 
“In some patients with COPD, type 2 inflammation may increase exacerbation risk and may be indicated by elevated blood eosinophil counts,” said researchers. 
“In some patients with COPD,...
07/07/2023
First Report Managed Care
News
Exploring the Cost-Effectiveness of Acalabrutinib Regimens for Treatment-Naive CLL
07/31/2023
Acalabrutinib monotherapy may be a cost-effective treatment option for Medicare patients with treatment-naïve chronic lymphocytic leukemia, according to recent findings.
Acalabrutinib monotherapy may be a cost-effective treatment option for Medicare patients with treatment-naïve chronic lymphocytic leukemia, according to recent findings.
Acalabrutinib monotherapy may be...
07/31/2023
First Report Managed Care

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use